Regulatory

NATCO Pharma receives USFDA EIR with VAI classification for Visakhapatnam FDF unit

The company had received Four observations in the Form 483

  • By IPP Bureau | November 21, 2026

NATCO Pharma Limited receives Establishment Inspection Report (EIR) from US FDA Inspection at our Visakhapatnam, Andhra Pradesh, FDF Unit

The U.S. Food and Drug Administration (FDA) had conducted an inspection at the FDF manufacturing plant located in Parawada, Visakhapatnam, Andhra Pradesh, India, which was conducted from August 17th – August 21st, 2026.

On conclusion of the inspection, the company had received Four observations in the Form 483. We hereby notify that the company has received EIR from the U.S. FDA on the classification as Voluntary Action Indicated (VAI).

Upcoming E-conference

Other Related stories

Startup

Digitization

Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
(L-R) Manoj Kumar Panicker, General Manager, South Asia, Cytiva and Dr. Sanjib Banerjee, Chief Operating Officer (Biopharma Services), Veeda Lifesciences.